Nephrology

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Condition:   Metastatic Prostate Cancer
Interventions:   Drug: Niraparib;   Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

November 22, 2018 / by / in
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Condition:   Influenza
Interventions:   Drug: Baloxavir Marboxil;   Other: Placebo
Sponsor:   Hoffmann-La Roche
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 26, 2018 / by / in
Chronic Kidney Disease (CKD) Platelet Study

Conditions:   Chronic Kidney Diseases;   Heart Attack;   Stroke, Ischemic
Interventions:   Drug: Ticagrelor 90mg;   Drug: Clopidogrel 75mg;   Drug: Aspirin 81 mg
Sponsors:   University of Arkansas;   American Society of Nephrology
Recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

August 29, 2018 / by / in
Crossover Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease

Conditions:   Chronic Kidney Disease;   Sarcopenia;   Frailty
Interventions:   Dietary Supplement: CoQ10;   Dietary Supplement: Nicotinamide riboside;   Dietary Supplement: Placebo
Sponsors:   University of Washington;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

July 6, 2018 / by / in
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

Condition:   Resistant Hypertension
Interventions:   Drug: Aprocitentan 12.5 mg;   Drug: Aprocitentan 25 mg;   Drug: Placebo
Sponsors:   Idorsia Pharmaceuticals Ltd.;   Janssen Biotech, Inc.
Recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

July 5, 2018 / by / in
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Conditions:   Anemia;   Renal Insufficiency, Chronic
Intervention:   Drug: Mircera
Sponsor:   Hoffmann-La Roche
Not yet recruiting
ClinicalTrials.gov: Nephrology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 12, 2018 / by / in